ABSTRACT
While SARS-CoV-2 infection continues to circulate around the world, there are still many uncertainties on how to treat the patients with this potentially deadly virus, and more importantly, for how long! COVID-19 causes many different symptoms, among which coagulopathy seems to play an essential role in the survival prognosis of patients. While medical centers worldwide have developed various algorithms for preventing thrombosis in COVID-19 patients, there are still no clear guidelines on the length of thromboprophylaxis therapy, target groups who should receive suitable anticoagulant prophylaxis, and even the choice of the most appropriate agent for such treatment. [ABSTRACT FROM AUTHOR] Copyright of Asian Journal of Medical Sciences is the property of Manipal Colleges of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
